Needham Maintains Buy on Globus Medical, Raises Price Target to $117

Benzinga Newsdesk www.benzinga.com Positive 72.1%

Neg 0% Neu 0% Pos 72.1%

Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $114 to $117.